• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For April 2, 2024

    4/2/24 6:25:53 AM ET
    $ABVX
    $AIM
    $ALLG
    $CALM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABVX alert in real time by email

    Companies Reporting Before The Bell

    • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.

    • Allego (NYSE:ALLG) is projected to report quarterly loss at $0.04 per share on revenue of $83.79 million.

    • Gryphon Digital Mining (NASDAQ:GRYP) is expected to report earnings for its fourth quarter.

    • AIM ImmunoTech (AMEX:AIM) is estimated to report quarterly loss at $0.15 per share on revenue of $40 thousand.

    • Paychex (NASDAQ:PAYX) is expected to report quarterly earnings at $1.37 per share on revenue of $1.46 billion.

    • Abivax (NASDAQ:ABVX) is likely to report quarterly loss at $2.14 per share on revenue of $4.88 million.

    Companies Reporting After The Bell

    • Cal-Maine Foods (NASDAQ:CALM) is projected to report quarterly earnings at $2.46 per share on revenue of $692.35 million.

    • Dave & Buster's Enter (NASDAQ:PLAY) is likely to report quarterly earnings at $1.10 per share on revenue of $602.61 million.

    • Vicinity Motor (NASDAQ:VEV) is expected to report quarterly loss at $0.06 per share on revenue of $12.62 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVX
    $AIM
    $ALLG
    $CALM

    CompanyDatePrice TargetRatingAnalyst
    Paychex Inc.
    $PAYX
    1/27/2026$98.00Underweight
    Cantor Fitzgerald
    Dave & Buster's Entertainment Inc.
    $PLAY
    1/16/2026$30.00Hold → Buy
    The Benchmark Company
    Paychex Inc.
    $PAYX
    12/9/2025$140.00 → $121.00Market Perform
    BMO Capital Markets
    Cal-Maine Foods Inc.
    $CALM
    12/1/2025$100.00Buy
    The Benchmark Company
    Abivax SA
    $ABVX
    11/24/2025Buy
    Truist
    Abivax SA
    $ABVX
    11/6/2025$176.00Outperform
    Wolfe Research
    Paychex Inc.
    $PAYX
    10/23/2025$139.00Neutral
    Citigroup
    Paychex Inc.
    $PAYX
    10/22/2025$128.00Underweight
    Wells Fargo
    More analyst ratings

    $ABVX
    $AIM
    $ALLG
    $CALM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bonadio Tom bought $98,498 worth of shares (1,000 units at $98.50), increasing direct ownership by 5% to 21,504 units (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:03 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Director Doody Joseph bought $98,760 worth of Common Stock - Family Trust (1,000 units at $98.76) (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:05 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $ABVX
    $AIM
    $ALLG
    $CALM
    SEC Filings

    View All

    SEC Form EFFECT filed by AIM ImmunoTech Inc.

    EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/11/26 12:15:22 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    2/9/26 7:59:25 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVX
    $AIM
    $ALLG
    $CALM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Announces Commencement of Rights Offering

    OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").  Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share ("Common Stock"), and to holders of certain options and warrants that have the right to participate in the Rights O

    2/11/26 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM's strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTPresenter: Thomas K. Equels, MS JD, Chief Executive Officer Registration Link: Here S

    2/6/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVX
    $AIM
    $ALLG
    $CALM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonadio Tom bought $98,498 worth of shares (1,000 units at $98.50), increasing direct ownership by 5% to 21,504 units (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:03 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Director Doody Joseph bought $98,760 worth of Common Stock - Family Trust (1,000 units at $98.76) (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:05 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    SVP, Chief Legal Officer Rodriguez Rodolfo Jr bought $14,673 worth of shares (730 units at $20.10), increasing direct ownership by 5% to 14,500 units (SEC Form 4)

    4 - Dave & Buster's Entertainment, Inc. (0001525769) (Issuer)

    1/20/26 4:30:17 PM ET
    $PLAY
    Restaurants
    Consumer Discretionary

    $ABVX
    $AIM
    $ALLG
    $CALM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Paychex with a new price target

    Cantor Fitzgerald initiated coverage of Paychex with a rating of Underweight and set a new price target of $98.00

    1/27/26 8:48:32 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Dave & Buster's upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Dave & Buster's from Hold to Buy and set a new price target of $30.00

    1/16/26 8:58:56 AM ET
    $PLAY
    Restaurants
    Consumer Discretionary

    BMO Capital Markets reiterated coverage on Paychex with a new price target

    BMO Capital Markets reiterated coverage of Paychex with a rating of Market Perform and set a new price target of $121.00 from $140.00 previously

    12/9/25 8:28:42 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $ABVX
    $AIM
    $ALLG
    $CALM
    Leadership Updates

    Live Leadership Updates

    View All

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Paychex Expands Board of Directors, Appoints New Member

    Experienced executive, J. Michael Hansen, appointed to Paychex Board of Directors Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today that the company's Board of Directors has voted to expand to 11 members from 10 members. The Board has also appointed J. Michael Hansen to fill the new position as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119850035/en/ Mr. Hansen brings deep financial expertise, having served as Executive Vice President & Chief Financial Officer (CFO) of Cintas Corporation (NASDAQ:CTAS) for more than 10 years. Upon his retirem

    1/20/26 8:30:00 AM ET
    $CTAS
    $PAYX
    Garments and Clothing
    Industrials
    Diversified Commercial Services

    Paychex and PayPal Team Up to Bring Direct Deposit Alternatives Into Paychex Flex® Perks

    Paychex Flex Perks expands to 25 employee benefit offerings with PayPal integration Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today a new partnership with PayPal (NASDAQ:PYPL) within its Paychex Flex® Perks platform, Paychex's digital marketplace of curated employee benefits. Through this collaboration, employees of Paychex customers have the ability to easily set up PayPal Direct Deposit, providing up to two-day early access to their paychecks. According to the Federal Deposit Insurance Corporation, approximately 5.6 million U.S. households were unbanked in 2023 where no one in the household owned a checking or savings account at

    1/8/26 9:00:00 AM ET
    $PAYX
    $PYPL
    Diversified Commercial Services
    Industrials

    $ABVX
    $AIM
    $ALLG
    $CALM
    Financials

    Live finance-specific insights

    View All

    Paychex Announces $1 Billion Stock Repurchase Authorization and Declares Quarterly Dividend

    Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management ("HCM") company, today announced that its Board of Directors has authorized the purchase of up to $1 billion of the Company's common stock. The new authorization replaces the prior 2024 authorization to repurchase $400 million of the Company's common stock. In addition, the Board has declared a regular quarterly cash dividend on Paychex common stock of $1.08 per share, payable on February 27, 2026, to shareholders of record as of January 28, 2026. "For many years, we have maintained a long-standing commitment to delivering outstanding value to our investors," said John Gibson, Paychex President and CEO. "Today's n

    1/16/26 9:15:00 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

    MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School

    1/13/26 7:00:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cal-Maine Foods Reports Second Quarter Fiscal 2026 Results

    RIDGELAND, Miss., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM) ("Cal-Maine Foods," "we," "us," "our" or the "company"), the largest egg company in the United States and a leading player in the egg-based food industry, today reported results for its fiscal 2026 second quarter, ended November 29, 2025. Unless otherwise indicated, all comparisons are to the comparable period of fiscal 2025. Strategic Execution Highlights Continued focus on sales diversification and mix shift, expected to strengthen earnings durability and predictability over time In the second quarter of fiscal 2026 Shell egg sales represented 84.4% of total net sales, down 1,030 basis pointsSpeci

    1/7/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    $ABVX
    $AIM
    $ALLG
    $CALM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dave & Buster's Entertainment Inc.

    SC 13G/A - Dave & Buster's Entertainment, Inc. (0001525769) (Subject)

    11/14/24 4:15:21 PM ET
    $PLAY
    Restaurants
    Consumer Discretionary

    SEC Form SC 13G filed by AIM ImmunoTech Inc.

    SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

    11/14/24 3:21:36 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care